Nicolas Fischer, Ph.D.CEO at Light Chain Bioscience
Profile
After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering.
At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience where he acts as CEO.
Agenda Sessions
Engaging Adaptive and Innate Immune Systems with Bispecific Antibodies Targeting CD28 or CD47
, 2:30pmView Session